AstraZeneca | Investor Event Presentation Deck | 52 slides · page 32 of 52
Clinical trial data presentation showing PFS outcomes for Arm 1 (chemo + bev) vs Arm 3 (chemo + bev + durvalumab + olaparib).
Conference presentation · before_after · analyze_data · dense density
Slide locked Sign in to view
Slide schematic 5/5
chart 2/2 disclaimer 1/1 title 2/2
Components 5
line line disclaimer action-title headline
Tools 0
∅
No tools
No canon tool match is anchored to this slide.
Metrics 0
∅
No metrics
No metric insight is anchored to this slide.
Frameworks 1